A three-month study into how Peptest can be used to diagnose gastro-oesophageal reflux disease has begun in China, following an official launch in August.
The launch took place at the ‘Normal range reference of Chinese PGI research conference’ on 12 August 2017 at the Crowne Plaza Sea View hotel in Yantai, China.
The conference, overseen Dr Zhong Nanshan, an academician of Chinese Academy of Engineering, was also attended by Professor Qiuping Wang from Nanjing General Hospital and Professor Kefang Lai from The First Affiliate Hospital of Guangzhou Medical University.
Professor Alyn H Morice, Head of Respiratory Medicine and the Centre for Cardiovascular & Metabolic Research (CCMR) at HYMS, based at the University of Hull, was also at the conference and presented a briefing report on the application of Peptest in gastro-oesophageal reflux disease testing.
Advocated by Dr Zhong Nanshan, Jiangsu Maxhealth Pharmaceuticals Company will conduct a three-month study across nine hospitals centres in China, including Nanjing General Hospital and Shanghai Tongji Hospital.